Acrux Female Testosterone program featured in independent industry article

Acrux’s Female Testosterone program has been featured in an in-depth article by TRT Catalog examining the potential significance of the program as it advances toward Phase 3 development.

The article highlights:

• Acrux’s Female Testosterone product is targeting Hypoactive Sexual Desire Disorder, or HSDD, in peri- and post-menopausal women.

• There is currently no FDA-approved systemic testosterone product specifically for women in the United States.

• Acrux has completed Phase 1 and Phase 2 development.

• FDA feedback has provided a basis for progression into Phase 3 and a pathway toward US registration.

• The product uses Acrux’s Metered Dose Transdermal System, or MDTS, designed to provide precise transdermal dosing.

• Acrux is seeking a commercial partner with an established women’s health presence to support Phase 3 development and commercialisation.

The article also examines the history of previous attempts to develop testosterone therapies for women and the potential significance of a purpose-designed, FDA-approved product.

Read the full article: https://trtcatalog.com/learn/acrux-female-testosterone-phase-3-hsdd